The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

Survey finds a strong need for data unification, multi-cloud adoption, AI-driven transformation, and metadata control as organizations seek to maximi ...

Bailard Inc. increased its stake in Regeneron Pharmaceuticals by 10.1% in Q4, raising its holdings to 13,422 shares.

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

In a much-anticipated decision, the First Circuit unanimously ruled the government and relators must prove that a violation ...

The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

Maya Ajmera, President & CEO of Society for Science and Executive Publisher of Science News, chatted with Walter “Ted” Carter Jr., President of The Ohio ...

The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis ...

OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic ...

Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...

Nixon High’s Austlynn Quiroz won the Laredo ISD Science Fair and will compete internationally with her bioplastic project.